Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: axial spondyloarthritis

Reactive Arthritis: Chronic or Self-Limiting?

Michael J. Cammarata, MD  |  June 8, 2025

Reactive arthritis has proved to be a diagnostic & therapeutic challenge due to its diverse presentations.

Filed under:Axial SpondyloarthritisConditions Tagged with:biologic DMARDsdisease managementextra-articular manifestationsGlucocorticoidsHLA-B27infectious etiologymusculoskeletal manifestationsNSAIDsReactive arthritisspondyloarthritissulfasalazine

Editor's Pick

Large International Study Says Flares Rare After COVID Vaccination

Catherine Kolonko  |  April 3, 2025

‘Patients with rheumatologic diseases are rightfully concerned about the risk of flares after getting their COVID vaccines, especially after holding immune modulators,’ says says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘A new study is reassuring that flares are rare, even after holding or discontinuing immune modulators.’ The development of a vaccine for…

Filed under:ConditionsResearch Rheum Tagged with:COVID-19Flaresresearch reviewsvaccination

Flares Rare After COVID Vaccination

Catherine Kolonko  |  March 7, 2025

The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceGuidelinesResearch ReviewsResearch Rheum Tagged with:COVID-19flarevaccination

Precision Medicine on a Population Level

Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR  |  February 6, 2025

Guest columnists Dr. Daniel Solomon & Dr. Andrew Concoff discuss the potential of technology, such as mobile health apps, to enhance remote care & improve access for underserved patients.

Filed under:OpinionPractice ManagementPractice SupportSpeak Out RheumTechnologyWorkforceWorkforce Tagged with:healthcare accessPrecision Medicine

Precision Medicine on a Population Level: Can Digital Health Technology Improve Access to Rheumatologic Care?

Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR  |  January 16, 2025

Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…

Filed under:ConditionsOpinionPractice SupportRheumatoid ArthritisSpeak Out RheumTechnology Tagged with:mPROscheduling app

Should We Manage Men & Women Differently?

Samantha C. Shapiro, MD  |  November 22, 2024

Experts address how sex differences affect the clinical presentation, diagnosis, response to therapy and experience of illness for patients with PsA.

Filed under:ACR ConvergenceConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 PsApatient carePsoriatic ArthritisSex DifferencesWomen

The 2024 ACR Awards of Distinction

Patrice Fusillo  |  November 18, 2024

The 2024 ACR Awards of Distinction honor members for their outstanding contributions to the field of rheumatology.

Filed under:ACR ConvergenceAwardsCareerMeeting ReportsProfiles Tagged with:ACR Convergence 2024Awards

The Management of Psoriatic Arthritis: A Review

Samantha C. Shapiro, MD  |  November 17, 2024

WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 PsA

15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions

Michele B. Kaufman, PharmD, BCGP  |  October 17, 2024

Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:EULAREULAR 2024Safetyupadacitinib

Measures of Success

Jason Liebowitz, MD, FACR  |  September 24, 2024

Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherGuidanceMeeting Reports Tagged with:APLARAPLAR 2024AS Resource CenterAsia Pacific League of Associations for Rheumatology (APLAR)axial spondyloarthritis (SpA)Diagnosisspondyloarthritis (SpA)Treat-to-Target

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 19
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences